Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 2,514 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy
Interventions: K-877 CR Tablet A, K-877 CR Tablet B, K-877 CR Tablet E, K-877 IR Tablet; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Health Behavior, Wellness, Psychological, Substance Use
Interventions: Cue reactivity paradigm; Other
Lead sponsor: Brown University; Other
Eligibility: 13 Years to 16 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Childhood Apraxia of Speech
Interventions: Speech Motor Chaining without Biofeedback, Biofeedback, Distributed Practice, Massed --> Distributed Practice; Behavioral
Lead sponsor: Syracuse University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Healthy Volunteers
Interventions: Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference); Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Stress
Interventions: Personalized Trial ABCCBA, Personalized Trial CBAABC, Stress Management Techniques with No Randomization Sequence (or order); Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Opiate Dependence
Interventions: SL spray, SL film; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Crohns Disease
Interventions: Afimkibart; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Dothan, Alabama • Hamden, Connecticut • Kissimmee, Florida + 2 more

Conditions: Healthy Volunteers
Interventions: DC-806, Itraconazole, Carbamazepine; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteers, Alzheimer Disease
Interventions: LY3202626, Placebo (Part A, B, C), Itraconazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Migraine
Interventions: K-645 100 mg, K-645 10 mg, Placebo; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 18
States / cities: Oceanside, California • Atlanta, Georgia • Stockbridge, Georgia + 15 more

Conditions: Tremor, Essential, Parkinson's Disease
Interventions: Automatic DRT/VIM target-recognition method using MR-SISET and ML approaches, Routine clinical MRI protocol; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Obsessive-Compulsive Disorder
Interventions: Summit RC+S System with ECoG Paddles, One Month Blinded Discontinuation Period:; Device · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Providence, Rhode Island • Houston, Texas

Conditions: Healthy Participants
Interventions: Casdatifan; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Macular Degeneration
Interventions: Proparacaine Ophthalmic, Tetracaine Ophthalmic, Lidocaine 4%, Lidocaine 2% Injectable Solution; Drug
Lead sponsor: Lahey Clinic; Other
Eligibility: 40 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Arlington, Massachusetts • Burlington, Massachusetts • Peabody, Massachusetts

Conditions: Insomnia, Insomnia, Psychophysiological, Sleep Disorder
Interventions: Vinyasa yoga group, Non-active control group; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Naltrexone, Methylphenidate Abuse
Interventions: Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421; Drug
Lead sponsor: Avekshan LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Lu AG06474, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Relapsed or Refractory Lymphoma
Interventions: HMPL-523, Rabeprazole; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Dyslipidaemias
Interventions: GSK256073; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Airway Control
Interventions: Not listed
Lead sponsor: Vidacare Corporation; Industry
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Corpus Christi, Texas • El Paso, Texas

Conditions: Parent-Child Relations, Partner Communication, Parenting
Interventions: 24/7 Dad; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Insomnia Disorder
Interventions: ACT-541468, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 65 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Brandon, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more

Conditions: Bipolar Disorder
Interventions: Continuous Theta Burst Stimulation (cTBS), Sham Continuous Theta Burst Stimulation (Sham cTBS); Device
Lead sponsor: Mary Phillips, MD MD (Cantab); Other
Eligibility: 18 Years to 35 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Compare the Pharmacokinetic of K-877 Controlled Release (CR) and Immediate Release (IR) Tablets in Healthy Adults.

Teen Health Choices & Wellness

Treating Childhood Apraxia of Speech

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

Personalized Trials for Stress Management Against Standard of Care

Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

A Study of K-645 in the Treatment of Multiple Migraine Attacks

Mapping the Target for the MRgFUS Treatment of Tremor

Phase II Adaptive Deep Brain Stimulation for Obsessive-Compulsive Disorder

A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants

Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection

The Yoga and Insomnia Study

Study for Naltrexone on the Abuse Potential of Methylphenidate

Safety and Tolerability of Lu AG06474 in Healthy Young Men

HMPL-523 Food Effect and Proton Pump Inhibitor Study

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Observational Study of Rapid Sequence Intubation Drug Delivery Using Intraosseous and Intravenous Access.

Improving Father-Child and Father-Partner Relationships Among Black and Hispanic Fathers

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Effects of Theta Burst Stimulation on the Brain, Behavior, and Clinical Symptoms in Adults With Bipolar Disorder